Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
Natera has enrolled the first patients in SIGNAL-ER 101, a prospective, interventional study evaluating MRD-guided therapy de-escalation in early-stage breast cancer. The study aims to determine if MRD-negative patients can safely defer adjuvant CDK4/6 inhibitor therapy, potentially avoiding serious adverse events and high costs associated with overtreatment. SIGNAL-ER 101 plans to enroll approximately 725 patients across 50 U.S.
Key figures
- Drug Name
- Signatera
- Phase Of Trial
- Prospective, single-arm, multi-center
- Study sites
- 50
- Target enrollment
- 725
- Treatment cost reference
- $400,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.